

MicroRNA profiling of novel African American and Caucasian
reveals a reciprocal regulatory relationship of *miR-15*

Oncotarget

5, 3512-3525

DOI: [10.18632/oncotarget.1953](https://doi.org/10.18632/oncotarget.1953)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Expression and clinical significance of microRNA-152 in supraglottic laryngeal carcinoma. <i>Tumor Biology</i> , 2014, 35, 11075-11079.	0.8	11
2	Novel RNA Markers in Prostate Cancer: Functional Considerations and Clinical Translation. <i>BioMed Research International</i> , 2014, 2014, 1-12.	0.9	12
3	An integrated genome-wide approach to discover deregulated microRNAs in non-small cell lung cancer: Clinical significance of miR-23b-3p deregulation. <i>Scientific Reports</i> , 2015, 5, 13236.	1.6	32
4	MicroRNA-410 functions as a tumor suppressor by targeting angiotensin II type 1 receptor in pancreatic cancer. <i>IUBMB Life</i> , 2015, 67, 42-53.	1.5	55
5	Role of MicroRNAs in Prostate Cancer Pathogenesis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 261-270.	0.9	37
6	Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2016, 16, 1385-1402.	0.9	20
7	Evaluation of Plasma miR-21 and miR-152 as Diagnostic Biomarkers for Common Types of Human Cancers. <i>Journal of Cancer</i> , 2016, 7, 490-499.	1.2	68
8	Prostate Cancer in African American Men: The Effect of Androgens and microRNAs on Epidermal Growth Factor Signaling. <i>Hormones and Cancer</i> , 2016, 7, 296-304.	4.9	5
9	A functional microRNA library screen reveals miR-410 as a novel anti-apoptotic regulator of cholangiocarcinoma. <i>BMC Cancer</i> , 2016, 16, 353.	1.1	29
10	miR-152 as a tumor suppressor microRNA: Target recognition and regulation in cancer. <i>Oncology Letters</i> , 2016, 11, 3911-3916.	0.8	61
11	Epigenetic basis of cancer health disparities: Looking beyond genetic differences. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 16-28.	3.3	45
12	Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 361, 386-397.	1.3	23
13	Clinical significance of miRNA host gene promoter methylation in prostate cancer. <i>Human Molecular Genetics</i> , 2017, 26, 2451-2461.	1.4	43
14	Recent scenario of microRNA as diagnostic and prognostic biomarkers of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 92-101.	0.8	35
15	Long non-coding RNA H19 promotes the proliferation and invasion of breast cancer through upregulating DNMT1 expression by sponging miR-152. <i>Journal of Biochemical and Molecular Toxicology</i> , 2017, 31, e21933.	1.4	80
16	MicroRNAs in prostate cancer: Functional role as biomarkers. <i>Cancer Letters</i> , 2017, 407, 9-20.	3.2	114
17	Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans. <i>Clinical Cancer Research</i> , 2017, 23, 7412-7425.	3.2	83
18	Resveratrol and pterostilbene as a microRNA-mediated chemopreventive and therapeutic strategy in prostate cancer. <i>Annals of the New York Academy of Sciences</i> , 2017, 1403, 15-26.	1.8	44

#	ARTICLE	IF	CITATIONS
19	Proteomic characterization of paired non-malignant and malignant African-American prostate epithelial cell lines distinguishes them by structural proteins. <i>BMC Cancer</i> , 2017, 17, 480.	1.1	6
20	Racial health disparities in ovarian cancer: not just black and white. <i>Journal of Ovarian Research</i> , 2017, 10, 58.	1.3	30
21	miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 212-229.	3.0	14
22	Racial disparities disruptive genes in prostate carcinogenesis. <i>Frontiers in Bioscience - Scholar</i> , 2017, 9, 244-253.	0.8	8
23	Racial disparities in prostate cancer a molecular perspective. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 772-782.	3.0	87
24	MicroRNA-guided gene expression in prostate cancer: Literature and database overview. <i>Journal of Gene Medicine</i> , 2018, 20, e3016.	1.4	19
25	A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97. <i>Clinical Epigenetics</i> , 2018, 10, 40.	1.8	39
26	A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer. <i>Scientific Reports</i> , 2018, 8, 6653.	1.6	62
27	Lung cancer health disparities. <i>Carcinogenesis</i> , 2018, 39, 741-751.	1.3	66
28	The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 2763-2786.	1.2	78
29	Identification of tumor suppressive role of microRNA-132 and its target gene in tumorigenesis of prostate cancer. <i>International Journal of Molecular Medicine</i> , 2018, 41, 2429-2433.	1.8	19
30	MiR-152 functioning as a tumor suppressor that interacts with DNMT1 in nasopharyngeal carcinoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1733-1741.	1.0	16
31	Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model. <i>Journal of Translational Medicine</i> , 2018, 16, 134.	1.8	41
32	MicroRNAs as Diagnostic, Prognostic, and Therapeutic Biomarkers in Prostate Cancer. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2019, 29, 127-139.	0.4	66
34	Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1154.	1.8	51
35	Epigenetics of Prostate Cancer and Novel Chemopreventive and Therapeutic Approaches. , 2019, , 287-308.		1
36	Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies. <i>Cancer Reports</i> , 2021, 4, e1340.	0.6	13
37	The role of HOTAIR/miR-152-3p/LIN28B in regulating the progression of endometrial squamous carcinoma. <i>Archives of Medical Science</i> , 2021, 17, 434-448.	0.4	8

#	ARTICLE	IF	CITATIONS
38	Semen sampling as a simple, noninvasive surrogate for prostate health screening. <i>Systems Biology in Reproductive Medicine</i> , 2021, 67, 354-365.	1.0	3
39	The Pursuit of Health Equity and Equality in Urologic Oncology: Where We Have Been and Where We Are Going. <i>European Urology Focus</i> , 2021, 7, 929-936.	1.6	1
40	miR-148a, miR-152 and miR-200b promote prostate cancer metastasis by targeting DNMT1 and PTEN expression. <i>Oncology Letters</i> , 2021, 22, 805.	0.8	18
41	Role of Alternative Splicing in Prostate Cancer Aggressiveness and Drug Resistance in African Americans. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1164, 119-139.	0.8	14
42	Kaiso, a transcriptional repressor, promotes cell migration and invasion of prostate cancer cells through regulation of miR-31 expression. <i>Oncotarget</i> , 2016, 7, 5677-5689.	0.8	44
45	Molecular mechanisms involving prostate cancer racial disparity. <i>American Journal of Clinical and Experimental Urology</i> , 2017, 5, 34-48.	0.4	18
47	Pathogen-Induced Epigenetic Modifications in Cancers: Implications for Prevention, Detection and Treatment of Cancers in Africa. <i>Cancers</i> , 2021, 13, 6051.	1.7	8
48	Differential expression of microRNA between triple negative breast cancer patients of African American and European American descent. <i>Biotechnic and Histochemistry</i> , 2022, 97, 1-10.	0.7	2
49	MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data. <i>British Journal of Cancer</i> , 2022, 126, 502-513.	2.9	28
50	Role of Precision Oncology in Type II Endometrial and Prostate Cancers in the African Population: Global Cancer Genomics Disparities. <i>International Journal of Molecular Sciences</i> , 2022, 23, 628.	1.8	7
51	Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 736951.	1.6	8
52	miR-152 hypomethylation as a mechanism for non-syndromic cleft lip and palate. <i>Epigenetics</i> , 2022, 17, 2278-2295.	1.3	2
53	Molecular Insight into Drug Resistance Mechanism Conferred by Aberrant PIK3CD Splice Variant in African American Prostate Cancer. <i>Cancers</i> , 2023, 15, 1337.	1.7	2
54	Investigating miR-9 as a mediator in laryngeal cancer health disparities. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
58	Translational Efforts in Precision Medicine to Address Disparities. , 2023, , 49-66.		0